On March 6, the NMPA website showed that Novo Nordisk’s insulin icodec plus semaglutide, IcoSema, had been approved in China. Based on public information and clinical trial progress, the Insight database inferred that the approved indication is for the treatment of adult patients with type 2 diabetes whose disease is inadequately controlled on basal insulin or a GLP-1 receptor agonist, on the basis of diet and exercise.
IcoSema is a combination product of the once-weekly basal insulin insulin icodec and the once-weekly GLP-1 receptor agonist semaglutide. The maximum weekly dose delivered in a single injection is 350 dose units, corresponding to 350 units of insulin icodec and 1.0 mg of semaglutide. In November 2025, the product was approved by the European Medicines Agency for the treatment of adults with type 2 diabetes, becoming the world’s first once-weekly basal insulin and GLP-1 receptor agonist combination product.
The approval by the European Commission was based on positive results from the COMBINE 3a clinical trial program. All three trials in the program met their primary endpoints, demonstrating that once-weekly IcoSema was superior to its individual components in lowering blood glucose, as measured by changes in HbA1c, and non-inferior to a daily basal-bolus insulin regimen in glycemic reduction.
In addition, IcoSema showed greater weight loss and a lower incidence of clinically significant or severe hypoglycemia. Across the entire 3a clinical trial program, once-weekly IcoSema also demonstrated a safe and well-tolerated profile.
At CDS 2025, the 27th Academic Meeting of the Chinese Diabetes Society, a post hoc analysis of the Chinese subgroup in the COMBINE 1 study was presented. This was also the first disclosure of efficacy and safety data for IcoSema in a Chinese population. The results showed that the Chinese subgroup was consistent with the global COMBINE 1 findings:
In Chinese patients with type 2 diabetes previously treated with basal insulin, IcoSema achieved significantly greater reductions in HbA1c and body weight than insulin icodec alone.
In terms of target achievement and composite target achievement, the IcoSema group was significantly better than the insulin icodec group in the proportion of patients achieving HbA1c below 7% and in the composite endpoint of HbA1c below 7% without weight gain and without clinically significant or severe hypoglycemia.
In terms of insulin dose, the IcoSema group used significantly less insulin than the insulin icodec group.
For safety, from baseline to Week 57, the incidence of clinically significant or severe hypoglycemia was similar between the IcoSema group and the insulin icodec group. Adverse events observed in the IcoSema group were consistent with the characteristics of the individual components, and no new safety issues were identified.
Novo Nordisk started from diabetes drugs and later built a weight-management product line centered on semaglutide. As the newest member of its once-weekly treatment portfolio, IcoSema provides a new treatment option for patients with type 2 diabetes who require insulin therapy.
Novo Nordisk is now continuing to accelerate iteration and expansion of its metabolic pipeline through a dual strategy of internal development and external in-licensing, while actively advancing new indications for metabolism-related diseases.